Get In Touch

Gene Therapy Market - Snapshot

Introduction of new production, availability of reimbursement together with high occurrences of cancer are estimated to propel growth of the global gene therapy market in the years to come. Gene therapy refers to an experimental technique, which utilizes genes for the prevention and treatment of various diseases. It is expected that in the near future, this technology could assist doctors to place a gene into the cells of a patient for the purpose of his treatment. This therapy could be used as an alternative to surgery or drugs. Scientists are examining various approaches to this therapy, which could comprise

  • Introduction of a new gene into the body to combat a disease
  • Inactivating a mutated malfunctioning gene
  • Replacement of a disease causing mutated gene with a healthy copy of the same

Gene therapy has emerged as a promising treatment option for a large number of diseases such as certain viral infections, certain cancers, and inherited disorders. This factor is likely to work in favor of the global gene therapy market in the years to come.

Progress in Gene-editing and Genomics Tools to Stoke Demand of Gene Therapy                                                               

CAR T-cell use has recently garnered considerable attention from the sponsors following the exhibition of its immense promise in the treatment of several diseases. The promising future of CAR T-cell is estimated to amplify the growth opportunities of the global gene therapy market. Sponsors hail CAR T-cell use as a brand new business model of the future.

In the pipeline of pharmaceutical industry, gene therapy account for a considerable share and this trend is likely to continue in the years to come. In addition, significant advancement has been made in the fields of cellular and molecular biology is likely to fuel growth of the global gene therapy market in the years to come. rapid technological progress made in the gene-editing and genomics tools are further estimated to drive the demand for gene therapy.

Global Gene Therapy Market – Snapshot

Expanding at a stellar, double-digits CAGR (Compound Annual Growth Rate) of 40% over the forecast period of 2018 to 2026, the global gene therapy market is a dizzying trajectory, marking out a rosy landscape for players operating in the playfield. As per a Transparency Market Research report, based on extensive primary and secondary research, states that over the period states, the market would accrue a worth of USD 5164.03 million – a steep and impressive increase from the USD 17 million worth noted in 2017.

Fixing defective genes via introduction of new and healthy ones to fix severe genetic and chronic disorders is seeing an upward curve in demand for reasons of improved medical outcomes, major leaps in terms of technological advancement and minimal die-effects as compared to alternatives. Some of the most significant alternatives include surgery, and drug use.

Some of the most significant factors that the analysts of the report note include focused efforts towards marketing and commercialization, and a slew of approvals of new products hitting the global gene therapy market. Additionally, there are factors such as growing demand experienced for this treatment by a large pool of patients.

It is pertinent to note here that the global gene therapy market is consolidated and is dependent on clinincal research and development of the highest standards in order to chart growth. And, some of the players that operate the market landscape, and are into significant research projects include Gilead Sciences, Inc., Novartis AG, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., CELGENE CORPORATION, and Orchard Therapeutics Limited.

gene therapy market

Yescarta to Dominate Global Gene Therapy Market over the Forecast Period

The global gene therapy market report by TMR is segmented based on type, application, and region. The former includes the only five products that have been approved so far for commercial use. These include Gendicine, Yescarta, Strimvelis, Kymriah, and Luxturna. Riding the first mover benefits, Yescarta helf the dominant position in the market in 2017, and the trend will continue, adding more worth to the sub-segment. This is the product that brought out the initial CAR T therapy in the market for large B-cell lymphoma that relapse.

It is worth noting here that as per the global gene therapy market report, the high incidence of DLBCL and massive commercialization efforts directed towards Yescarta, particularly in Europe, will contribute positively and significantly to the overall growth of the global gene therapy market. The other sub-segment to make a mark over the global gene therapy market landscape will be Luxturna, owing to rising awareness levels and massive efforts towards comercialization.

Europe to be Ahead of the Global Gene Therapy Market Growth Curve over the Forecast Period

The global gene therapy market’s regional segmentation includes incisive growth insights into some of the most significant areas that will shape up the overall growth in the market. These include North America, Europe, and Rest of the World. Researchers involved with the preparation of report claim that a massive chunk of about 40% would be accounted for by Europe over the forecast period. Some of the factors backing-up the market dominance of the region include high incidence of non Hodgkin lymphoma and increase in number of treatment centers into gene therapy.

This growth would be followed by North America region, owing to huge contributions from the United States of America which witnesses about 7500 cases of refractory DLBCL each year. These are ones that qualify for the CAR T therapy.

Gene Therapy Market - Overview

This report studies the current as well as future prospects of the global gene therapy market. Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of gene therapy products and new entrants planning to enter the market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. This section also provides the overall information and data analysis of the global gene therapy market regarding leading segments based on product, application, and region.

The global gene therapy market has been segmented based on product, application, and region. In terms of product, the global market has been classified into Yescarta, Kymriah, Luxturna, Strimvelis, and Gendicine. In terms of application, the global market has been divided into ophthalmology, oncology, and adenosine deaminase?deficient severe combined immunodeficiency (ADA-SCID).

The market revenue for each product was estimated using bottom-up approach. The revenue generated by each product and application has been calculated considering marketing approvals of the products, sales, number of patients treated, cost of products, and pattern in different regions. The bottom-up approach for determining the country market size was studied using various market indicators obtained from secondary sources, which include different products and their applications and their cost variations in major country/region, prevalence and incidence in major countries for eligible patients with relapsed or refractory large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL),  acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL) and head and neck cancer. Revenues of all publicly listed market players were obtained through secondary sources and analyzed for gene therapy specific revenues by narrowing down to revenue percentage for product segment through extensive secondary analysis of annual reports, investor presentations, press releases, primary interviews, and others. Data triangulation is based on secondary research (top-down and bottom-up approaches) and primary research. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment has been provided for the period from 2017 to 2026. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2018 to 2026, considering 2017 as the base year.

The market overview section of the report explores market dynamics such as drivers, restraints, opportunities, and key trends that have a strong impact on the gene therapy market and could influence it in the near future. Market attractiveness analysis has been provided to explain the intensity of competition across different regions. The competitive scenario among different players is evaluated through market share analysis in the competitive landscape section of the report. These factors are likely to help market players take strategic decisions to strengthen their positions and expand their shares in the global gene therapy market.

In terms of region, the global gene therapy market has been segmented into the U.S., Europe, and rest of world. The market size and forecast for each of these regions has been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the overview section. This section of the report also provides the market attractiveness analysis and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global gene therapy market.

Major players operating in the global gene therapy market include Gilead Sciences, Inc., Novartis AG, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., CELGENE CORPORATION, and Orchard Therapeutics Limited.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

The global gene therapy market has been segmented as follows:

Product

  • Yescarta
  • Kymriah
  • Luxturna
  • Strimvelis
  • Gendicine

Application

  • Ophthalmology
  • Oncology
  • Adenosine Deaminase Deficient Severe Combined Immunodeficiency (ADA-SCID)

Region

  • U.S.
  • Europe
  • Rest of World

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives

2. Assumptions and Research Methodology

3. Executive Summary : Global Gene Therapy Market

4. Market Overview
     4.1. Introduction
            4.1.1. Gene Therapy Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Gene Therapy Market Analysis and Forecasts, 2017–2026

5. Market Outlook
     5.1.Clinical Trial Pipeline Analysis

6. Global Gene Therapy Market Analysis and Forecasts, by Product 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Gene Therapy Market Value Forecast, by Product, 2017–2026
            6.3.1. Yescarta
            6.3.2. Kymriah
            6.3.3. Luxturna
            6.3.4. Strimvelis
            6.3.5. Gendicine
     6.4. Market Attractiveness, by Product

7. Global Gene Therapy Market Analysis and Forecasts, by Application 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Gene Therapy Market Value Forecast, by Application, 2017–2026
            7.3.1. Ophthalmology
            7.3.2. Oncology
            7.3.3. Adenosine Deaminase?Deficient Severe Combined Immunodeficiency (ADA-SCID)
     7.4. Global Gene Therapy Market Attractiveness, by Application

8. U.S. Gene Therapy Market Analysis and Forecast
     8.1. Introduction
     8.2. U.S. Gene Therapy Market Value Forecast, by Product, 2017–2026
            8.2.1. Yescarta
            8.2.2. Kymriah
            8.2.3. Luxturna
            8.2.4. Strimvelis
            8.2.5. Gendicine
     8.3. U.S. Gene Therapy Market Value Forecast, by Application, 2017–2026
            7.3.1. Ophthalmology
            7.3.2. Oncology
            7.3.3. Adenosine Deaminase?Deficient Severe Combined Immunodeficiency (ADA-SCID)
     8.4. U.S. Gene Therapy Market Attractiveness Analysis 
            8.4.1. By Product 
            8.4.2. By Application

9. Europe Gene Therapy Market Analysis and Forecast
     9.1. Introduction
     9.2. Europe Gene Therapy Market Value Forecast, by Product, 2017–2026
            9.2.1. Yescarta
            9.2.2. Kymriah
            9.2.3. Luxturna
            9.2.4. Strimvelis
            9.2.5. Gendicine
     9.3. Europe Gene Therapy Market Value Forecast, by Application, 2017–2026
            9.3.1. Ophthalmology
            9.3.2. Oncology
            9.3.3. Adenosine Deaminase?Deficient Severe Combined Immunodeficiency (ADA-SCID)
     9.4. Europe Gene Therapy Market Attractiveness Analysis 
            9.4.1. By Product 
            9.4.2. By Application

10. Rest of World Gene Therapy Market Analysis and Forecast
     10.1. Introduction
     10.2. Rest of World Gene Therapy Market Value Forecast, by Product, 2017–2026
            10.2.1. Yescarta
            10.2.2. Kymriah
            10.2.3. Luxturna
            10.2.4. Strimvelis
            10.2.5. Gendicine
     10.3. Rest of World Gene Therapy Market Value Forecast, by Application, 2017–2026
            10.3.1. Ophthalmology
            10.3.2. Oncology
            10.3.3. Adenosine Deaminase?Deficient Severe Combined Immunodeficiency (ADA-SCID)
     10.4. Rest of World Gene Therapy Market Attractiveness Analysis 
            10.4.1. By Product 
            10.4.2. By Application

11. Competition Landscape
     11.1.Market Player – Competition Matrix (By Tier and Size of companies)
     11.2.Market Share Analysis, by Company (2017)
     11.3. Company Profiles
            11.3.1. Novartis AG

  •      Company Overview (HQ, Business Segments, Employee Strength)
  •      Product Portfolio
  •      SWOT Analysis
  •      Strategic Overview
  •      Financial Overview

            11.3.2. Orchard Therapeutics Limited.
     Company Overview (HQ, Business Segments, Employee Strength)
     Product Portfolio
     SWOT Analysis
     Strategic Overview
            11.3.3. CELGENE CORPORATION

  •      Company Overview (HQ, Business Segments, Employee Strength)
  •      Product Portfolio
  •      SWOT Analysis
  •      Financial Overview
  •      Strategic Overview

            11.3.4. Spark Therapeutics, Inc.

  •      Company Overview (HQ, Business Segments, Employee Strength)
  •      Product Portfolio
  •      SWOT Analysis
  •      Financial Overview
  •      Strategic Overview

            11.3.5. Gilead Sciences, Inc.

  •      Company Overview (HQ, Business Segments, Employee Strength)
  •      Product Portfolio
  •      SWOT Analysis
  •      Financial Overview
  •      Strategic Overview

            11.3.6. Sibiono GeneTech Co. Ltd.

  • Company Overview (HQ, Business Segments, Employee Strength)
  •      Product Portfolio
  •      SWOT Analysis
  •      Strategic Overview

List of Tables

Table 01: Pipeline Analysis: Gene therapy Candidates (1/8)
Table 02: Pipeline Analysis: Gene therapy Candidates (2/8)
Table 03: Pipeline Analysis: Gene therapy Candidates (3/8)
Table 04: Pipeline Analysis: Gene therapy Candidates (4/8)
Table 05: Pipeline Analysis: Gene therapy Candidates (5/8)
Table 06: Pipeline Analysis: Gene therapy Candidates (6/8)
Table 07: Pipeline Analysis: Gene therapy Candidates (7/8)
Table 08: Pipeline Analysis: Gene therapy Candidates (8/8)
Table 09: Global Gene Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2026
Table 10: Global Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2017–2026
Table 11: U.S. Gene Therapy Market Size (U.S.$ Mn) Forecast, by Product, 2017–2026
Table 12: U.S. Gene Therapy Market Size (U.S.$ Mn) Forecast, by Application, 2017–2026
Table 13: Europe Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2017–2026
Table 14: Europe Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2017–2026
Table 15: Rest of the World Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2017–2026
Table 16: Rest of the World Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2017–2026

List of Figures

Figure 01: Market Segmentation: Global Gene Therapy Market
Figure 02: Research Methodology: Global Gene Therapy Market
Figure 03: Analysis by Product
Figure 04: Analysis by Application
Figure 05: Analysis by Region
Figure 06: Key Industry Developments
Figure 07: Drivers and Restraints: Global Gene Therapy Market
Figure 08: Global Gene Therapy Market Value (US$ Mn) Forecast, 2017–2026
Figure 09: Global Gene Therapy Market Value Share, by Product (2017)
Figure 10: Global Gene Therapy Market Value Share, by Application (2017)
Figure 11: Global Gene Therapy Market Value Share, by Country/Region (2017)
Figure 12: Key Findings: Global Gene Therapy Market, by Product 
Figure 13: Introduction: Global Gene Therapy Market, by Product 
Figure 14: Global Gene Therapy Market Value Share Analysis, by Product, 2017 and 2026
Figure 15: Global Gene Therapy Market Attractiveness Analysis, by Product, 2018–2026
Figure 16: Global Gene Therapy Market Revenue (US$ Mn), by Yescarta, 2017–2026
Figure 17: Global Gene Therapy Market Revenue (US$ Mn), by Kymriah, 2017–2026
Figure 18: Global Gene Therapy Market Revenue (US$ Mn), by Luxturna, 2017–2026
Figure 19: Global Gene Therapy Market Revenue (US$ Mn), by Strimvelis, 2017–2026
Figure 20: Global Gene Therapy Market Revenue (US$ Mn), by Gendicine, 2017–2026
Figure 21: Key Findings: Global Gene Therapy Market, by Application
Figure 22: Introduction: Global Gene Therapy Market, by Application
Figure 23: Global Gene Therapy Market Value Share Analysis, by Application, 2017 and 2026
Figure 24: Global Gene Therapy Market Attractiveness Analysis, by Product, 2018–2026
Figure 25: Global Gene Therapy Market Revenue (US$ Mn), by Ophthalmology, 2017–2026
Figure 26: Global Gene Therapy Market Revenue (US$ Mn), by Oncology, 2017–2026
Figure 27: Global Gene Therapy Market Revenue (US$ Mn), by ADA-SCID, 2017–2026
Figure 28: U.S. Gene Therapy Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
Figure 29: U.S. Gene Therapy Market Value Share Analysis, by Product, 2017 and 2026
Figure 30: U.S. Gene Therapy Market Value Share Analysis, by Product, 2017 and 2026
Figure 31: U.S. Gene Therapy Market Value Share Analysis, by Application, 2017 and 2026
Figure 32: U.S. Gene Therapy Market Attractiveness Analysis, by Application, 2018–2026
Figure 33: Europe Gene Therapy Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
Figure 34: Europe Gene Therapy Market Value Share Analysis, by Product, 2017 and 2026
Figure 35: Europe Gene Therapy Market Attractiveness Analysis, by Product, 2018-2026
Figure 36: Europe Gene Therapy Market Value Share Analysis, by Application, 2017 and 2026
Figure 37: Europe Gene Therapy Market Attractiveness Analysis, by Application, 2018–2026
Figure 38: Rest of the World Gene Therapy Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
Figure 39: Rest of the World Gene Therapy Market Value Share Analysis, by Product, 2017 and 2026
Figure 40: Rest of the World Gene Therapy Market Attractiveness Analysis, by Product, 2018-2026
Figure 41: Rest of the World Gene Therapy Market Value Share Analysis, by Application, 2017 and 2026
Figure 42: Rest of the World Gene Therapy Market Attractiveness Analysis, by Application, 2018–2026
Figure 43: Competition Matrix: Global Gene Therapy Market 
Figure 44: Novartis AG, Company Details
Figure 45: Novartis AG, Product Portfolio
Figure 46: Novartis AG, Breakdown of Net Sales, by Geography (2017)
Figure 47: Novartis AG, Breakdown of Net Sales, by Business Segment (2017)
Figure 48: Novartis AG, Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2017
Figure 49: Novartis AG, R&D Intensity and Sales & Marketing Intensity – Company Level, 2016–2017
Figure 50: Novartis AG, SWOT Analysis
Figure 51: Orchard Therapeutics Limited, Company Details
Figure 52: Orchard Therapeutics Limited, Product Portfolio
Figure 53: Orchard Therapeutics Limited, SWOT Analysis
Figure 54: CELGENE CORPORATION, Company Details
Figure 55: CELGENE CORPORATION, Product Portfolio
Figure 56: CELGENE CORPORATION, Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 57: CELGENE CORPORATION, Breakdown of Net Sales, by Key Products (2017)
Figure 58: CELGENE CORPORATION, Breakdown of Net Sales, by Geography (2017)
Figure 59: CELGENE CORPORATION, R&D Intensity and Sales & Marketing Intensity: Company Level, 2016-2017
Figure 60: CELGENE CORPORATION, SWOT Analysis
Figure 61: Spark Therapeutics, Inc., Company Details
Figure 62: Spark Therapeutics, Inc., Product Portfolio
Figure 63: Spark Therapeutics, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
Figure 64: Spark Therapeutics, Inc., R&D Expenditure, 2016–2017
Figure 65: Spark Therapeutics, Inc., SWOT Analysis
Figure 66: Gilead Sciences, Inc., Company Details
Figure 67: Gilead Sciences, Inc., Product Portfolio
Figure 68: Gilead Sciences, Inc., Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2017
Figure 69: Gilead Sciences, Inc., R&D Expenditure (US$ Bn), 2016–2017
Figure 70: Gilead Sciences, Inc., SWOT Analysis
Figure 71: Sibiono GeneTech Co. Ltd, Company Details
Figure 72: Sibiono GeneTech Co. Ltd, Product Portfolio
Figure 73: Sibiono GeneTech Co. Ltd, SWOT Analysis

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Gene Therapy Market